Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

The long march to surrogates of meaningful clinical outcomes in MS trials: are we there yet?

Wolinsky JS, Beck CA.

Neurology. 2011 Nov 1;77(18):1658-9. doi: 10.1212/WNL.0b013e3182364a63. Epub 2011 Oct 5. No abstract available.

PMID:
21975199
2.

Combined MRI lesions and relapses as a surrogate for disability in MS.

Ebers GC, Scalfari A, Daumer M, Lederer C.

Neurology. 2012 Apr 24;78(17):1367; author reply 1367. doi: 10.1212/WNL.0b013e318255b4fe. No abstract available.

PMID:
22529206
3.

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, De Stefano N.

Neurology. 2011 Nov 1;77(18):1684-90. doi: 10.1212/WNL.0b013e31823648b9. Epub 2011 Oct 5.

PMID:
21975200
4.

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.

Neurology. 2006 Sep 26;67(6):944-53.

PMID:
17000959
5.

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A; Investigators of the 16-Year Long-Term Follow-Up Study.

Neurology. 2010 Jun 8;74(23):1877-85. doi: 10.1212/WNL.0b013e3181e240d0.

PMID:
20530324
6.

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.

Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.

Neurol Sci. 2005 Dec;26 Suppl 4:S174-8.

PMID:
16388353
7.

Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.

Carmona O, Casado V, Moral E, Alonso-Magdalena L, Martínez-Yélamos A, Martínez-Yélamos S, Martín-Ozaeta G, Arbizu T.

Eur Neurol. 2008;60(6):279-84. doi: 10.1159/000157881. Epub 2008 Sep 27.

PMID:
18824855
8.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.

PMID:
20488825
9.

PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.

Cohen BA, Rivera VM.

Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018. Review. Erratum in: Curr Med Res Opin. 2010 Aug;26(8):1826. Dosage error in article text.

PMID:
20121658
10.

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

Brown MG, Murray TJ, Sketris IS, Fisk JD, LeBlanc JC, Schwartz CE, Skedgel C.

Int J Technol Assess Health Care. 2000 Summer;16(3):751-67.

PMID:
11028131
11.

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.

Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.

Arch Neurol. 2008 Feb;65(2):199-204. Epub 2007 Dec 10.

PMID:
18071030
12.

Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.

Rudick RA, Kappos L, Kinkel R, Clanet M, Phillips JT, Herndon RM, Sandrock AW, Munschauer FE 3rd.

Mult Scler. 2011 Mar;17(3):353-60. doi: 10.1177/1352458510384605. Epub 2010 Oct 21.

PMID:
20965959
13.

[The role of interferon beta in the treatment of multiple sclerosis].

Seeldrayers P.

Rev Med Brux. 1999 Sep;20(4):A264-7. Review. French.

PMID:
10523902
14.

Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.

Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X.

Ann Neurol. 2006 Feb;59(2):344-52.

PMID:
16437558
15.

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.

Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Sheeder J, Miller D, McCabe K, Serra A, Campion MK, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd.

Neurology. 2000 Jul 25;55(2):185-92.

PMID:
10908888
16.

[Relapsing-remitting inflammatory disease of the central nervous system with normal MRI: multiple sclerosis or phenocopy in a series of 15 patients].

Lebrun C, Bourg V, Chanalet S, Chatel M.

Rev Neurol (Paris). 2003 Apr;159(4):397-404. Review. French.

PMID:
12773868
17.

[PRISMS study. Interferon beta-1a therapy in relapsing-remitting multiple sclerosis].

Limmroth V.

Internist (Berl). 2001 Feb;42(2):305-7. Review. German. No abstract available.

PMID:
11244885
18.

The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.

Kieseier BC.

Expert Rev Neurother. 2014 Jan;14(1):105-20. doi: 10.1586/14737175.2014.869478. Review.

PMID:
24417500
19.

Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.

Qu ZX, Pliskin N, Jensen MW, White D, Arnason BG.

Arch Neurol. 2001 Jan;58(1):87-90.

PMID:
11176940
20.

The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy.

Trojano M, Paolicelli D, Zimatore GB, De Robertis F, Fuiani A, Di Monte E, Livrea P.

Neurol Sci. 2005 Dec;26 Suppl 4:S179-82.

PMID:
16388354

Supplemental Content

Support Center